Effect of oral ferric citrate on serum phosphorus in hemodialysis patients

multicenter, randomized, double-blind, placebo-controlled study

Chien Te Lee, I. Wen Wu, Shou Shan Chiang, Yu Sen Peng, Kuo Hsiung Shu, Ming Ju Wu, Mai Szu Wu

研究成果: 雜誌貢獻文章

19 引文 (Scopus)

摘要

Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.

Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.

Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p 

Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.

原文英語
頁(從 - 到)105-113
頁數9
期刊Journal of Nephrology
28
發行號1
DOIs
出版狀態已發佈 - 2014

指紋

Phosphorus
Renal Dialysis
Hyperphosphatemia
Placebos
Serum
Transferrin
Ferritins
Phosphates
Taiwan
Chronic Kidney Failure
Dialysis
Randomized Controlled Trials
Maintenance
ferric citrate
Calcium
Safety
Therapeutics

ASJC Scopus subject areas

  • Nephrology

引用此文

Effect of oral ferric citrate on serum phosphorus in hemodialysis patients : multicenter, randomized, double-blind, placebo-controlled study. / Lee, Chien Te; Wu, I. Wen; Chiang, Shou Shan; Peng, Yu Sen; Shu, Kuo Hsiung; Wu, Ming Ju; Wu, Mai Szu.

於: Journal of Nephrology, 卷 28, 編號 1, 2014, p. 105-113.

研究成果: 雜誌貢獻文章

Lee, Chien Te ; Wu, I. Wen ; Chiang, Shou Shan ; Peng, Yu Sen ; Shu, Kuo Hsiung ; Wu, Ming Ju ; Wu, Mai Szu. / Effect of oral ferric citrate on serum phosphorus in hemodialysis patients : multicenter, randomized, double-blind, placebo-controlled study. 於: Journal of Nephrology. 2014 ; 卷 28, 編號 1. 頁 105-113.
@article{eec4a46dfb2a47179e7a6237a3dbf68d,
title = "Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study",
abstract = "Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.",
keywords = "Ferric citrate, Hemodialysis, Iron metabolism, Phosphate",
author = "Lee, {Chien Te} and Wu, {I. Wen} and Chiang, {Shou Shan} and Peng, {Yu Sen} and Shu, {Kuo Hsiung} and Wu, {Ming Ju} and Wu, {Mai Szu}",
year = "2014",
doi = "10.1007/s40620-014-0108-6",
language = "English",
volume = "28",
pages = "105--113",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Effect of oral ferric citrate on serum phosphorus in hemodialysis patients

T2 - multicenter, randomized, double-blind, placebo-controlled study

AU - Lee, Chien Te

AU - Wu, I. Wen

AU - Chiang, Shou Shan

AU - Peng, Yu Sen

AU - Shu, Kuo Hsiung

AU - Wu, Ming Ju

AU - Wu, Mai Szu

PY - 2014

Y1 - 2014

N2 - Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.

AB - Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.

KW - Ferric citrate

KW - Hemodialysis

KW - Iron metabolism

KW - Phosphate

UR - http://www.scopus.com/inward/record.url?scp=84922574601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922574601&partnerID=8YFLogxK

U2 - 10.1007/s40620-014-0108-6

DO - 10.1007/s40620-014-0108-6

M3 - Article

VL - 28

SP - 105

EP - 113

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 1

ER -